RE: Meta‐analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder
Abstract
To the Editor, Editor in chief, Neurourology and Urodynamics I browsed again the study published by Wang et al in the latest issue of Neurourology and Urodynamics. Mirabegron (50mg) vs solifenacin (5 mg) in treating overactive bladder (OAB) after 12 weeks of treatment was analyzed in the study, drawing a meaningful conclusion for the current treatment of OAB. However, the author made a fatal mistake in the quality level of Scaldazza et al and statistical analysis of mean volume voided per micturition. As stated in the original, “A, satisfied all quality criteria and had a low‐risk of bias; B, ambiguous about one or more quality criteria and had a moderate risk of bias,” Scaldazza et al is not a double‐blind study and the grade of the method of blinding was “B”. In table 2, “level of quality” of this article should be defined as “B” instead of “A”. For meta‐analysis, the study could be defined as a fixed‐effects model if P> .05, if not, a random‐effects model would be chosen. However, in fig. 2(D), the heterogeneity test showed P= .51 and a fixed‐effects model should be chosen instead of random‐effects model. Besides, I evaluated the quality of its methods on the basis of a critical appraisal tool‐AMSTAR 2. By AMSTAR 2, 15‐items score of the study were better evaluated by proper approaches and its outcome was simultaneously incorporated into the study by the analysis of sensitivity. All possible heterogeneity was also mentioned in the discussion part. To sum up, this article…
Read the paper
Related studies
- Sarcopenia, sarcopenic overweight/obesity and risk of cardiovascular disease and cardiac arrhythmia: A cross-sectional study
- Workplace Violence Is Associated With Impaired Work Functioning in Nurses: An Italian Cross-Sectional Study
- Vagus Nerve Dysfunction in the Post-COVID-19 Condition: a pilot cross sectional study
- Association Between Metabolic Associated Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study from NHANES 2017–2018
- Efficacy and safety of solifenacin succinate 10 mg once Daily: A multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder
- Association between triglyceride glucose‐body mass index and hypertension in Chinese adults: A cross‐sectional study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.